OPKO Health (OPK) Proxy filing summary

Voting matters and shareholder proposals

• Election of eleven directors for terms expiring at the 2027 annual meeting or until successors are elected and qualified.

• Approval of the 2026 Equity Incentive Plan.

• Advisory vote on executive compensation (say-on-pay) for named executive officers.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Provision for transaction of other business as may properly come before the meeting.

Board of directors and corporate governance

• Eleven nominees are recommended for election to the board, including individuals with medical, scientific, and business backgrounds.

Executive compensation and say-on-pay

• Shareholders are asked to approve a non-binding resolution on compensation for named executive officers.

• A new 2026 Equity Incentive Plan is proposed for approval.